Is magnesium neuroprotective following global and focal cerebral ischaemia? A review of published studies.

Neuroprotective activity with magnesium associated with animal models of cerebral ischaemia, seizure, perinatal hypoxia/ischaemia, subarachnoid haemorrhage and traumatic brain injury has provided the justification for clinical stroke trials. However, the recent IMAGES stroke clinical trial found magnesium to be largely ineffective. Hence, due to the negative stroke trial outcome, current FAST-MAG trial and our own experience with magnesium in cerebral ischaemia animal models, we thought it prudent to review these preclinical and clinical studies. We reviewed nine studies describing the use of magnesium following global cerebral ischaemia and fourteen following focal cerebral ischaemia. Four global ischaemia and six focal ischaemia studies did not show a significant neuroprotective effect with magnesium. In the majority of positive magnesium studies animal body temperature was not monitored post-ischaemia. Thus the effects of post-ischaemic hypothermia cannot be ruled out as a confounding factor in positive magnesium cerebral ischaemia studies. Moreover, data from our own laboratory indicates that magnesium is only neuroprotective when combined with post-ischaemic hypothermia. These data provide a possible explanation of why the IMAGES trial was largely unsuccessful, as current stroke patient management does not involve hypothermia induction. Future preclinical and clinical cerebral ischaemia trials with magnesium should consider combining treatment with mild hypothermia.     

氨苯砜综合征诊治探讨——附6例报告

目的：探讨氨苯砜综合征的诊治要点：方法：对6例氨苯砜综合征患者的临床资料进行回顾性分析。结果和结论：6例氨苯砜综合征患者均为中青年，从服药到出现症状的时间较长，为9～55日.6例患者均以高热起病，起病急骤、凶险，病初均有麻疹紫癜样皮疹，皮疹多形，严重者出现尼氏征阳性或阴性的大疱和（或）全身性红皮病样皮疹；均有浅表淋巴结肿大；多数患者有血液系统损害；并均有肝损害：确诊后及时停氨苯砜，给予足量肾上腺皮质激素和（或）大剂量免疫球蛋白静脉注射，以及支持对症处理，住院12～80（中位数53）日，4例痊愈，1例病情得到控制，另1例因治疗第2日自动出院放弃治疗，死于肝功能衰竭？提示氨苯砜综合征需要及时、正确处理，否则预后不良.     

A comparative study of using comet assay and gammaH2AX foci formation in the detection of N-methyl-N'-nitro-N-nitrosoguanidine-induced DNA damage.

Comet assay is a useful technique in the detection of DNA damages, particularly DNA strand breaks; and it has been utilized to show that a potent carcinogen N-methyl-N'-nitro-N-nitrosoguanidine (MNNG), can induce such damages. Recently, gammaH2AX foci formation has been suggested as another sensitive way to detect DNA double strand breaks (DSBs). However, there is no systematic comparison being conducted to evaluate the consistency of these two methods. Using MNNG as a model chemical, the sensitivity of neutral comet assay and gammaH2AX foci formation in detecting MNNG-induced damage was studied. It was found that at concentrations of 0.1 and 1 microg/ml, both methods can detect MNNG-induced damage in human amnion FL cells. However, at 0.1 microg/ml, comet assay revealed more percentage of cells with DNA damage than gammaH2AX fluorescence revealed. On the other hand, while gammaH2AX foci were readily formed at very early times by 10 microg/ml MNNG treatment, neutral comet assay did not detect any significant DNA damage at the same time points. In addition, 10 microg/ml MNNG induced a distinct whole nuclei staining pattern of gammaH2AX, a type of DNA damage which was not detected by neutral comet assay but could be detected by alkaline comet assay. Therefore, gammaH2AX may be used as a sensitive indicator for DNA damage.     

米氮平与氯丙咪嗪治疗抑郁和焦虑共病的疗效对照

目的比较米氮平、氯丙咪嗪抗抑郁和焦虑的共病作用和不良反应。方法65例同时符合抑郁症与焦虑障碍诊断标准的门诊患者,HAMD17项评分总分≥17分,≤23分、HAMA总分≥14分, ≤29分。分别随机给予口服米氮平(简称A组)和氯丙咪嗪(简称B组)。研究全程为期4周。疗效评定按HAMD、HAMA得分≤7分为治愈,减分50％为有效。数据进行X2及t检验。结果入组时两组 HAMD、HAMA得分无显著性差异(t=0．32,P>0．05),治疗第1周A组HAMD得分下降比B组明显, HAMA得分下降更为明显。治疗第2周开始A组HAMD、HAMA得分下降均比B组来的显著。第4周末A组临床治愈18例(56．3％,18／32),临床有效28例(87．5％,28／32)。B组临床治愈15例(45．5％, 15／33)临床有效27例(81．9％,27／33)。米氮平组有效率87．5％,氯丙咪嗪组有效率81．9％,无显著性差异(X2分别为0．76、0．40,P>0．05)。B组的不良反应例数及严重程度均远高于A组。结论对具有抑郁和焦虑共病的患者可用米氮平治疗。     

微波干燥法对腊叶标本压制的实验研究

目的：寻求一种不受气候条件影响而能成功制作腊叶标本的新技术。方法：采用微波干燥法，即用微波炉，由创制的直径31cm瓦楞纸板、吸水纸与玻璃皿组成的压制程序进行微波干燥。结果：微波干燥法可用于腊叶标本压制，且优于传统的常规腊叶标本压制方法。结论：本研究为腊叶标本的制作提供了一个新方法，收到了便捷、高效、且保色的理想效果。     

兔女郎的前世今生

《花花公子》杂志曾经是西方性解放运动的产物，这本杂志及其创办的兔女郎俱乐部在相当长的时期里曾经影响着西方上流社会的生活，成为著名的声色享乐之地。     

新的高强度高选择性阿片μ受体激动剂[11C]-羟甲芬太尼的合成

羟甲芬太尼(I)是一个新的高强度高选择性阿片μ受体激动剂。本文用cis-A-N-[1-(2-羟基-2-苯乙基)-3-甲基-4-哌啶基]-苯胺(II)或cis-N-[1-(苯甲酰甲基)-3-甲基-4-哌啶基]-苯胺(III)作为前体合成了[¹¹C]-羟甲芬太尼,以便用正电子发射断层扫描(PET)来观察μ受体。通过水解cis-A-羟甲芬太尼(I)和cis-N-[1-(苯甲酰甲基)-3-甲基-4-哌啶]-N-苯基丙酰胺(cis-IV)的4-N-丙酰基分别获得II和III。溴乙烷的格氏试剂与回旋加速器产生的[¹¹C]-二氧化碳反应后继而直接加入邻苯二甲酸二酰氯和2,6-二叔丁基吡啶生成同位素标记中间体[¹¹C]-丙酰氯。[¹¹C]-丙酰氯与OH-前体(II)反应后再经HPLC分离纯化直接得[¹¹C]-羟甲芬太尼;[¹¹C]-丙酰氯与酮-前体(III)反应后,再用硼氢化钠甲醇溶液处理,然后进行HPLC分离纯化得[¹¹C]-羟甲芬太尼。两种方法均可获得ll.1～14.8GBq/μmol的特异性放射化学纯[¹¹C]-羟甲芬太尼。总共耗时为40～50min(EOB)。     

非洛地平缓释片在兔体内药物动力学和生物利用度比较

目的 比较几种国产非洛地平缓释片在兔体内的药物动力学和生物利用度.方法 用高效液相色谱法测定兔口服药物后血浆中的药物浓度,以普通非洛地平片作为参照,计算其药物动力学和生物利用度.结果 在1.0-80μg·L-1范围内,非洛地平血浆药物浓度与色谱峰高呈良好的线性关系.单剂量兔血浆中非洛地平缓释片动力学参数不同产品存在差异,相对于普通制剂的生物利用度分别为179%、162%、122%.结论 不同产品非洛地平缓释片药物动力学和生物利用度存在差别.     

霍奇金淋巴瘤组织中H／RS细胞与其背景细胞的微切割及其IgH基因重排检测

目的 从基因水平探讨霍奇金淋巴瘤(HL)组织中H／RS细胞(Hodgkin and Reed-Sternberg cells)是否起源于B细胞、H／RS细胞的克隆性以及与背景淋巴细胞的相互关系。方法 对33例经典霍奇金淋巴瘤(cHL)石蜡刮片组织进行IgH基因重排分析，并对其中6例重排阳性的病例经B细胞特异性激活蛋白(BSAP)免疫标记，将标记阳性的H／RS细胞和背景淋巴细胞进行微切割后进一步行IgH基因重排分析。结果 16例石蜡刮片组织IgH基因重排阳性。对6例经BSAP标记的cHL成功进行了微切割，其中19管H／RS细胞中，有14管出现重排阳性，细胞数目不同的各管阳性率无显著性差异(P=0．290)；12管背景淋巴细胞有2管出现重排阳性，H／RS细胞与背景淋巴细胞的阳性率有显著性差异(P=0．002)。结论 支持H／RS细胞来源于B细胞的理论，认为部分背景淋巴细胞可能具有瘤性增生活性，参与H／RS细胞的前体细胞组成。